Syndax Price Target (SNDX) Raised at Barclays Following Management Discussions

Syndax Pharmaceuticals stock (NASDAQ:SNDX) has been boosted by an updated analysis from Barclays, which raised its price target on the shares to $35 from $22, maintaining an Overweight rating. The adjustment reflects a revised model after discussions with the company's management. The stock has already demonstrated strong momentum in recent weeks, up 28.9% on the 1 month. 

Prior to this latest upgrade, Barclays had already increased its price target just a few weeks ago on November 4, from $19.00 to $22.00, influenced by Syndax's financial results and product pipeline. The company reported a 266.4% year-over-year revenue increase, reaching $45.87 million in the most recent quarter.

However, the company's negative net margin of 428.48% indicates ongoing profitability challenges. At that time, markets noted insider trading activities, including CEO Michael A. Metzger's sale of over 157,000 shares, representing a 34.50% reduction in his ownership.

Shifting Analyst Sentiments

UBS Group also adjusted its outlook on November 4, 2025, elevating its price target to $38.00 from $35.00, while maintaining a Buy rating. This revision suggested a substantial potential upside from the stock's then current price, driven by strong quarterly earnings. The company's EPS of ($0.70) surpassed analysts' expectations, alongside the significant revenue increase.

However, not all analysts share the same level of optimism. On November 12, 2025, JP Morgan lowered its price target for Syndax from $40.00 to $33.00, albeit whilst maintaining a bullish Overweight rating. 

The recent price target increases suggest a growing confidence in Syndax's prospects, driven by improving financial performance and promising product developments. The latest upgrade from Barclays, following discussions with management, could signify a deeper understanding of the company's strategic direction and future growth potential.